

increased PER2 levels and inhibited FcεRI signaling in mast cells or basophils (Figs 1 and 5 and see Fig E7) also suggested the predominant role of CK1δ in the mast cell/basophil clockwork. However, the precise roles of CK1δ in the mast cell/basophil clockwork remain to be determined.

The current findings also suggest that the antiallergic effects of glucocorticoids (and possibly also aminophylline) on mast cells depend on the functional mast cell clock, specifically PER2 upregulation by glucocorticoids. Previous studies have shown that treatment of BMDCs with glucocorticoids for long periods (eg, 6-24 hours) downregulated FcεRI expression and signaling, although the mechanisms are still unclear.³²⁻³⁴

In addition, in patients with nocturnal asthma, the optimal timing of steroid treatment was reported to be the early evening.³⁵ Thus it would be attractive to speculate that these antiallergic actions of glucocorticoids were mediated through its effects on the mast cell clock, which requires several hours to increase PER2 levels. Consistent with this idea, a recent study showed that DEX inhibited proinflammatory chemokine expression in airway epithelial cells, depending on intact epithelial clock function.³⁶ However, it remains to be determined to what extent the circadian clock function contributes to the antiallergic actions of glucocorticoids because glucocorticoids influence many key molecules and pathways involved in allergic inflammation.

Chronic administration (daily injections) of PF670462 restored circadian behavior in mice rendered behaviorally arrhythmic by genetic or functional disruption of the circadian timing system.¹⁵ The daily enhancement of PER2 levels mediated by CK1δ/ε inhibition could synchronize weak circadian oscillations in this case.¹⁵ Thus we speculate that acute injection of PF670462 might have some influence (although statistically not significant) on PER2 expression and PCA reactions in mast cell-specific *Clock*-mutated mice, as well as in control mice, which could be attributed to the variability of the data in PF670462-treated, mast cell-specific *Clock*-mutated mice (Fig 2). Therefore it will be interesting to investigate whether repeated injections of PF670462 restore PER2 levels and suppress PCA reactions in mast cell-specific *Clock*-mutated mice.

To minimize systemic adverse effects on the circadian clock, it would be most appropriate to administer "clock modifiers" locally. Indeed, we found that local administration of PF670462 successfully suppressed OVA-induced nasal rubbing and sneezing in a mouse model of allergic rhinitis without affecting daily rhythms in locomotor activity in mice (Fig 4 and data not shown). Given the strong influence of circadian rhythms on allergic diseases³⁷ and well-developed local treatment strategies (eg, intranasal, inhaled, or topical treatment), allergic diseases might be suitable targets for testing the therapeutic potential of clock modifiers. However, one of the limitations of this strategy is that particular clock modifiers, such as PF670462 or DEX, require several hours to alter the phase of the circadian clock (eg, increasing PER2 levels), and therefore the optimal timing of such treatment should be pursued to maximize their antiallergic effects.

In summary, this proof-of-concept study demonstrates that pharmacologically resetting (resynchronizing or phase shifting) the molecular clock in mast cells or basophils can suppress IgE-mediated allergic reactions. Thus we propose that manipulation of the clock selectively in mast cells or basophils might become a new approach to inhibit allergy. Additionally, this study suggests a novel mechanism underlying the antiallergic actions of

glucocorticoids (and possibly also aminophylline) that relies on the circadian clock, which might provide novel insight into the pharmacology of the drugs (eg, steroid resistance) in allergy.

We thank Kazuko Nakamura, Tomoko Tohno, Drs Katsuyo Doi and Mutsuko Hara, and Professors Shinji Shimada and Shuichiro Maeda for their valuable assistance.

Clinical implications: Manipulation of the molecular clock selectively in mast cells or basophils might become a new strategy for controlling IgE-mediated allergic diseases.

REFERENCES

1. Takahashi JS, Hong HK, Ko CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. *Nat Rev Genet* 2008;9:764-75.
2. Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. *Annu Rev Physiol* 2010;72:517-49.
3. Ukai H, Ueda HR. Systems biology of mammalian circadian clocks. *Annu Rev Physiol* 2010;72:579-603.
4. Arjona A, Silver AC, Walker WE, Fikrig E. Immunity's fourth dimension: approaching the circadian-immune connection. *Trends Immunol* 2012;33:607-12.
5. Scheiermann C, Kunisaki Y, Frenette PS. Circadian control of the immune system. *Nat Rev Immunol* 2013;13:190-8.
6. Curtis AM, Bellet MM, Sassone-Corsi P, O'Neill LA. Circadian clock proteins and immunity. *Immunity* 2014;40:178-86.
7. Bechtold DA, Gibbs JE, Loudon AS. Circadian dysfunction in disease. *Trends Pharmacol Sci* 2010;31:191-8.
8. Lee H, Chen R, Lee Y, Yoo S, Lee C. Essential roles of CK1δ and CK1ε in the mammalian circadian clock. *Proc Natl Acad Sci U S A* 2009;106:21359-64.
9. Nakamura Y, Harama D, Shimokawa N, Hara M, Suzuki R, Tahara Y, et al. Circadian clock gene *Period2* regulates a time-of-day-dependent variation in cutaneous anaphylactic reaction. *J Allergy Clin Immunol* 2011;127:1038-45.
10. Nakamura Y, Ishimaru K, Tahara Y, Shibata S, Nakao A. Disruption of the suprachiasmatic nucleus blunts a time of day-dependent variation in systemic anaphylactic reaction in mice. *J Immunol Res* 2014;2014:474217.
11. Nakamura Y, Nakano N, Ishimaru K, Hara M, Ikegami T, Tahara Y, et al. Circadian regulation of allergic reactions by the mast cell clock in mice. *J Allergy Clin Immunol* 2014;133:568-75.
12. Kraft S, Rana S, Jouvin MH, Kinet JP. The role of the FcεRIβ-chain in allergic diseases. *Int Arch Allergy Immunol* 2004;135:62-72.
13. Chen Z, Yoo SH, Takahashi JS. Small molecule modifiers of circadian clocks. *Cell Mol Life Sci* 2013;70:2985-98.
14. Isojima Y, Nakajima M, Ukai H, Fujishima H, Yamada RG, Masumoto KH, et al. CK1ε/δ-dependent phosphorylation is a temperature-insensitive, period-determining process in the mammalian circadian clock. *Proc Natl Acad Sci U S A* 2009;106:15744-9.
15. Meng QJ, Maywood ES, Bechtold DA, Lu WQ, Li J, Gibbs JE, et al. Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes. *Proc Natl Acad Sci U S A* 2010;107:15240-5.
16. Yoo SH, Yamazaki S, Lowrey PL, Shimomura K, Ko CH, Buhr ED, et al. PERIOD2::LUCIFERASE real-time reporting of circadian dynamics reveals persistent circadian oscillations in mouse peripheral tissues. *Proc Natl Acad Sci U S A* 2004;101:5339-46.
17. Vitaterna MH, King DP, Chang AM, Kornhauser JM, Lowrey PL, McDonald JD, et al. Mutagenesis and mapping of a mouse gene, *Clock*, essential for circadian behavior. *Science* 1994;264:719-25.
18. Rena G, Bain J, Elliott M, Cohen P. D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. *EMBO Rep* 2004;5:60-5.
19. Zheng B, Larkin DW, Albrecht U, Sun ZS, Sage M, Eichele G, et al. The *mPer2* gene encodes a functional component of the mammalian circadian clock. *Nature* 1999;400:169-73.
20. Walton KM, Fisher K, Rubitski D, Marconi M, Meng QJ, Sládek M, et al. Selective inhibition of casein kinase 1ε minimally alters circadian clock period. *J Pharmacol Exp Ther* 2009;330:430-9.
21. Koyanagi S, Hamdan AM, Horiguchi M, Kusunose N, Okamoto A, Matsunaga N, et al. cAMP-response element (CRE)-mediated transcription by activating transcription factor-4 (ATF4) is essential for circadian expression of the *Period2* gene. *J Biol Chem* 2011;286:32416-23.

22. Costa M, Manen CA, Russell DH. In vivo activation of cAMP-dependent protein kinase by aminophylline and 1-methyl, 3-isobutylxanthine. *Biochem Biophys Res Commun* 1975;65:75-81.
23. Miyata M, Hatsushika K, Ando T, Shimokawa N, Ohnuma Y, Katoh R, et al. Mast cell regulation of epithelial TSLP expression plays an important role in the development of allergic rhinitis. *Eur J Immunol* 2008;38:1487-92.
24. Ando N, Nakamura Y, Ishimaru K, Ogawa H, Okumura K, Shimada S, et al. Allergen-specific basophil reactivity exhibits daily variations in seasonal allergic rhinitis. *Allergy* 2015;70:319-22.
25. Hauswirth AW, Natter S, Ghannadan M, Majlesi Y, Schemthaner GH, Sperr WR, et al. Recombinant allergens promotes expression of CD203c on basophils in sensitized individuals. *J Allergy Clin Immunol* 2002;110:102-9.
26. Yamaguchi M, Lantz CS, Oettgen HC, Katona IM, Fleming T, Miyajima I, et al. IgE enhances mouse mast cell FcεRI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. *J Exp Med* 1997;185:663-72.
27. Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. *Nat Rev Immunol* 2007;7:93-104.
28. Rivera J, Fierro NA, Olivera A, Suzuki R. New insights on mast cell activation via the high affinity receptor for IgE. *Adv Immunol* 2008;98:85-120.
29. Turner H, Kinet JP. Signalling through the high-affinity IgE receptor FcεRI. *Nature* 1999;402:24-30.
30. Schmutz I, Ripperger JA, Baeriswyl-Aebischer S, Albrecht U. The mammalian clock component PERIOD2 coordinates circadian output by interaction with nuclear receptors. *Genes Dev* 2010;24:345-57.
31. Smadja Storz S, Tovin A, Mracek P, Alon S, Foulkes NS, Gothif Y. Casein kinase 1δ activity: a key element in the zebrafish circadian timing system. *PLoS One* 2013;8:e54189.
32. Benhamou M, Ninio E, Salem P, Hieblot C, Bessou G, Pitton C, et al. Decrease in IgE Fc receptor expression on mouse bone marrow-derived mast cells and inhibition of paf-acether formation and of β-hexosaminidase release by dexamethasone. *J Immunol* 1986;136:1385-92.
33. Robin JL, Seldin DC, Austen KF, Lewis RA. Regulation of mediator release from mouse bone marrow-derived mast cells by glucocorticoids. *J Immunol* 1985;135:2719-26.
34. Yamaguchi M, Hirai K, Komiya A, Miyamasu M, Furumoto Y, Teshima R, et al. Regulation of mouse mast cell surface FcεRI expression by dexamethasone. *Int Immunol* 2001;13:843-51.
35. Pincus DJ, Humeston TR, Martin RJ. Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. *J Allergy Clin Immunol* 1997;100:771-4.
36. Gibbs J, Ince L, Matthews L, Mei J, Bell T, Yang N, et al. An epithelial circadian clock controls pulmonary inflammation and glucocorticoid action. *Nat Med* 2014;20:919-26.
37. Nakao A, Nakamura Y, Shibata S. The circadian clock functions as a potent regulator of allergic reaction. *Allergy* 2015;70:467-73.

The Journal of Experimental Medicine

Correction: CLEC-2 in megakaryocytes is critical for maintenance of hematopoietic stem cells in the bone marrow
Ayako Nakamura-Ishizu, Keiyo Takubo, Hiroshi Kobayashi, Katsue Suzuki-Inoue, and Toshio Suda

Vol. 212, No. 12, November 16, 2015. Pages 2133–2146.

The authors regret that the affiliation “Department of Stem Cell Biology, Research Institute, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo 162-8655, Japan” for K. Takubo and H. Kobayashi was left out of the original publication. The authors also regret leaving out additional funding information for K. Takubo from MEXT and the National Center for Global Health and Medicine. The corrected Acknowledgments paragraph appears below. The HTML and PDF versions of this article have been corrected.

T. Suda is supported by the National Medical Research Council (NMRC) grant of Singapore Translational Research Investigator (STaR) Award Investigator. A. Nakamura-Ishizu was supported in part by a fellowship from the Japan Society for the Promotion of Science, a Grants-in-Aid for Scientific Research (25-40030 and 26713035), a research grant from the SENSHIN medical research foundation, a research grant from the Takeda Foundation, and a grant from the Naito Foundation. K. Takubo was supported in part by a Ministry of Education, Culture, Sports, Science and Technology (MEXT) Grant-in-Aid for Young Scientists (A). T. Suda and K. Takubo were supported in part by a MEXT Grant-in-Aid for Scientific Research (A) and a MEXT Grant-in-Aid for Scientific Research on Innovative Areas. K. Suzuki-Inoue was supported in part by the NEXT program (LS052). K. Takubo was supported in part by a MEXT Grant-in-Aid for Scientific Research (15H04861,26115005) and a Grant of the National Center for Global Health and Medicine (H26-001).

CLEC-2 in megakaryocytes is critical for maintenance of hematopoietic stem cells in the bone marrow

Ayako Nakamura-Ishizu,^{1,2,3*} Keiyo Takubo,^{2,5*} Hiroshi Kobayashi,^{2,5} Katsue Suzuki-Inoue,⁴ and Toshio Suda^{1,2,3}

¹Cancer Science Institute, National University of Singapore, Singapore 117599

²The Sakaguchi Laboratory, Department of Cell Differentiation, Keio University, Shinjuku-ku, Tokyo 160-8582, Japan

³International Research Center for Medical Sciences (IRCMS), Kumamoto University, Chuo-ku, Kumamoto City 860-0811, Japan

⁴Department of Clinical and Laboratory Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan

⁵Department of Stem Cell Biology, Research Institute, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo 162-8655, Japan

Hematopoietic stem cells (HSCs) depend on the bone marrow (BM) niche for their maintenance, proliferation, and differentiation. The BM niche is composed of nonhematopoietic and mature hematopoietic cells, including megakaryocytes (Mks). Thrombopoietin (Thpo) is a crucial cytokine produced by BM niche cells. However, the cellular source of Thpo, upon which HSCs primarily depend, is unclear. Moreover, no specific molecular pathway for the regulation of Thpo production in the BM has been identified. Here, we demonstrate that the membrane protein C-type lectin-like receptor-2 (CLEC-2) mediates the production of Thpo and other factors in Mks. Mice conditionally deleted for CLEC-2 in Mks (*Clec2^{MkΔ/Δ}*) produced lower levels of Thpo in Mks. CLEC-2-deficient Mks showed down-regulation of CLEC-2-related signaling molecules *Syk*, *Lcp2*, and *Plcg2*. Knockdown of these molecules in cultured Mks decreased expression of *Thpo*. *Clec2^{MkΔ/Δ}* mice exhibited reduced BM HSC quiescence and repopulation potential, along with extramedullary hematopoiesis. The low level of Thpo production may account for the decline in HSC potential in *Clec2^{MkΔ/Δ}* mice, as administration of recombinant Thpo to *Clec2^{MkΔ/Δ}* mice restored stem cell potential. Our study identifies CLEC-2 signaling as a novel molecular mechanism mediating the production of Thpo and other factors for the maintenance of HSCs.

Maintenance of hematopoietic stem cells (HSCs) within the adult BM is crucial for the healthy production of hematopoietic cells (Orkin and Zon, 2008). HSCs reside in a specialized microenvironment in the BM called the niche (Schofield, 1978). Along with cell-intrinsic programs, the niche influences the cell fate of HSCs, which in turn govern the homeostasis of the hematopoietic system (Nakamura-Ishizu et al., 2014a). The HSC niche is chiefly composed of nonhematopoietic cells, including immature osteoblasts (OBLs; Arai and Suda, 2007), endothelial cells (ECs; Butler et al., 2010; Ding et al., 2012), perivascular cells (Sugiyama et al., 2006; Ding et al., 2012), mesenchymal stem cells (MSCs; Méndez-Ferrer et al., 2010), sympathetic nervous cells (Katayama et al., 2006), adipocytes (Naveiras et al., 2009), and nonmyelinating Schwann cells (Yamazaki et al., 2011). Nonetheless, mature hematopoietic cells such as macrophages/monocytes (Chow et al., 2011), osteoclasts (Kollet et al., 2006), and regulatory T cells (Fujisaki et al., 2011) also regulate HSCs, albeit mainly in an indirect manner, through the

modulation of nonhematopoietic niche cells. Recently, mature megakaryocytes (Mks) were described as hematopoietic progeny that directly regulate HSC quiescence (Heazlewood et al., 2013; Bruns et al., 2014; Zhao et al., 2014; Nakamura-Ishizu et al., 2014b); one of the mechanisms underlying Mk niche function is the production of the cytokine thrombopoietin (Thpo) by Mks themselves (Nakamura-Ishizu et al., 2014b). However, among the Mk-related niche factors reported to date, no molecular mechanism that is specific to Mks has been identified.

Thpo is a crucial cytokine for both the maturation of Mks and the maintenance of quiescent HSCs (Zucker-Franklin and Kaushansky, 1996; Qian et al., 2007; Yoshihara et al., 2007). Thpo is produced in multiple organs, including the liver, kidney, spleen, and muscle (Nomura et al., 1997). Baseline production of serum Thpo is thought to be maintained by the liver and regulated in response to inflammatory stress or changes in glycosylation of aged platelets (Kaser et al., 2001; Stone et al., 2012; Grozovsky et al., 2015). Serum Thpo levels also fluctuate according to circulating platelet number: platelets sequester Thpo via the myeloproliferative leukemia virus oncogene (c-Mpl), the receptor for Thpo (Kuter and Rosenberg,

*A. Nakamura-Ishizu and K. Takubo contributed equally to this paper.

Correspondence to Toshio Suda: sudato@z3.keio.ac.jp; or Ayako Nakamura-Ishizu: ayaknatm@gmail.com

Abbreviations used: BMT, BM transplantation; EC, endothelial cell; HSC, hematopoietic stem cell; HSPC, hematopoietic stem and progenitor cell; IHC, immunohistochemistry; LT-HSC, long-term HSC; Mk, megakaryocyte; MNC, mononuclear cell; MSC, mesenchymal stem cell; OBL, osteoblast; PB, peripheral blood; Thpo, thrombopoietin.

© 2015 Nakamura-Ishizu et al. This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms>). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at <http://creativecommons.org/licenses/by-nc-sa/3.0/>).

1995; de Graaf et al., 2010), thereby lowering Thpo levels. Thus, platelet number is not as tightly regulated by Thpo production as erythrocyte number is by erythropoietin production (Fandrey and Bunn, 1993). It is likely that BM HSCs depend on Thpo, which is produced in the BM by niche cells. Depletion of circulating platelets by neuraminidase does not affect HSCs (Bruns et al., 2014), indicating that serum Thpo up-regulation through thrombocytopenia does not affect HSC maintenance. Moreover, HSCs reside near bone-lining OBLs and mature Mkcs, which both support HSCs by producing Thpo (Yoshihara et al., 2007; Nakamura-Ishizu et al., 2014b). However, the main cellular source of Thpo, upon which BM HSCs depend, and the molecular signaling pathway that mediates BM Thpo production remain elusive.

Recent studies showed that signals mediated through C-type lectin-like domain-containing receptors (CLEC-4H1 and CLEC-4H2; also known as Ashwell-Morell receptor) stimulate Thpo production in hepatocytes through recognition of desialylated platelets (Grozovsky et al., 2015). Platelets and Mkcs express CLEC-2 (Suzuki-Inoue et al., 2006, 2007), which is among the top 25 genes specifically expressed on Mkcs (Senis et al., 2007). Activation of platelet CLEC-2 through binding to sialylated podoplanin is essential for the segregation of lymphatic and blood vessels during development (Bertozzi et al., 2010; Suzuki-Inoue et al., 2010). CLEC-2-podoplanin signaling also functions in maintenance of lymphocyte- and dendritic cell-related responses in the stroma of lymph nodes (Acton et al., 2012, 2014; Herzog et al., 2013).

The significance of CLEC-2 expression on Mkcs in BM hematopoiesis, and whether it is involved in Thpo production in Mkcs, has not been previously explored. Here, we demonstrate that Mk-specific deficiency of CLEC-2 disrupts HSC quiescence and alters HSC potential as a result of defective Mk niche function. Moreover, we demonstrate that CLEC-2 signaling is involved in various molecular pathways for production of niche factors, including Thpo in Mkcs. Through the identification of CLEC-2, a novel Mk-specific factor, our data elucidate the organ-dependent production and function of Thpo and reinforce the idea that Mkcs contribute to a niche that regulates HSC quiescence.

RESULTS

CLEC-2 is highly expressed on BM Mkcs

CLEC-2 expression was detected in platelets, dendritic cells, and liver sinusoidal endothelia (Suzuki-Inoue et al., 2011); however, the expression of CLEC-2 in BM has not been previously investigated. Using immunohistochemistry (IHC), we observed expression of CLEC-2 protein on the surface of Mkcs and ECs in the BM (Fig. 1 A). Hematopoietic stem and progenitor cell (HSPC) fractions also expressed *Clec2* transcripts (Fig. 1 B). Flow cytometry analysis confirmed surface CLEC-2 expression on HSPCs (Fig. 1 C). CLEC-2 protein expression was also compared in various hematopoietic (Fig. 1 D) and niche cells (Fig. 1 E). Among the hematopoietic and niche cells, CLEC-2 expression on CD41⁺ Mkcs and ECs was significantly high.

We investigated mice deficient in CLEC-2 specifically in the Mk lineage (*PF4-Cre:Clec2^{fllox/fllox}* mice [*Clec2^{Mkd/Δ}*]), which are born and survive through adulthood (Osada et al., 2012). PCR analysis confirmed that *Clec2* deletion was specific to Mk lineages: deletion was detected in genomic DNA from CD41⁺ (glycoprotein IIb⁺) cells, but not LSK (Lineage negative, Sca-1⁺, c-Kit⁺) cells, in the BM of *Clec2^{Mkd/Δ}* mice (Fig. 1 F). CLEC-2 protein level was significantly reduced in platelets from *Clec2^{Mkd/Δ}* mice but retained in their long-term HSCs (LT-HSCs; Fig. 1 G). Deletion of CLEC-2 from Mkcs was also confirmed with IHC (Fig. 1 H). *Clec2^{Mkd/Δ}* mice exhibited mild thrombocytopenia along with anemia (Fig. 1 I).

CLEC-2-deficient mice have impaired Mk cell population

Because CLEC-2 is highly expressed in Mk lineages, we asked whether CLEC-2 deficiency altered the frequency and BM functions of Mk lineage cells. The frequencies and numbers of mature Mkcs and Mk progenitors (MkP and Pre MegE cells) were unaltered in *Clec2^{Mkd/Δ}* mice (Fig. 2, A–D), and total CD41⁺ Mk cell number was unaltered in *Clec2^{Mkd/Δ}* mice (Fig. 2 E). However, ploidy analysis revealed a reduced frequency of mature polyploid Mkcs with CLEC-2 deficiency (Fig. 2, F and G). IHC revealed a significant reduction in the number of Mkcs in the metaphyseal region of the BM in *Clec2^{Mkd/Δ}* mice (Fig. 2 H). These observations indicate that CLEC-2 deficiency modestly affects the maturation of Mkcs but drastically alters the distribution of Mkcs within the BM.

CLEC-2-deficient Mkcs exhibit impaired Thpo production and niche function

Mkcs can support HSC expansion in vitro, chiefly through the production of Thpo (Nakamura-Ishizu et al., 2014b). Hence, we asked whether CLEC-2 deficiency would alter the capacity of Mkcs to support HSCs in vitro. Addition of Mkcs to HSC cultures resulted in a Thpo-dependent increase in HSC number (Nakamura-Ishizu et al., 2014b). Accordingly, addition of *Clec2^{+/+}* Mkcs to cultured HSCs promoted proliferation, as indicated by expansion of LSK cells and LT-HSCs (Fig. 3, A and B). *Clec2*-deficient Mkcs exhibited a reduced capacity to stimulate HSPC proliferation and could not maintain LT-HSC populations (Fig. 3 B).

Next, we assessed whether *Clec2*-deficient Mkcs exhibited changes in the production of various niche factors. *Clec2*-deficient Mkcs exhibited a broad range of decrease in the gene expression of various niche factors, including *Angpt1*, *Cxcl12*, *IL-7*, *Spp1*, *Tnfr*, and *Pf4* (Fig. 3 C). Characteristically, *Clec2*-deficient Mkcs secreted less Thpo and altered Mk niche function. *Clec2*-deficient Mkcs exhibited significantly lower *Thpo* expression than Mkcs from *Clec2^{+/+}* mice (Fig. 3 C). Furthermore, wild-type Mkcs treated with CLEC-2-stimulating antibodies expressed significantly higher levels of *Thpo* transcripts (Fig. 3 D). The decrease of Thpo protein expression in CLEC-2-deficient Mkcs was confirmed by IHC (Fig. 3 E).




Figure 1. CLEC-2 is expressed in Mks and is specifically deleted in Mks of *Clec2^{Mkd/Δ}* mice. (A) IHC of BM of 10-wk-old wild-type mice. CLEC-2 stains for VE-cadherin-positive ECs (arrowheads) and VE-cadherin-negative Mks (arrows). Enlargement of the dotted box is shown in the top right panel. CLEC-2 stains for CD41-positive Mks (bottom right). (B) Relative expression of CLEC-2 (*Clec1b*) transcripts in various hematopoietic cells. (C) Calculation of mean fluorescence ratios of CLEC-2 in various HSPC populations as measured by flow cytometry. (D and E) Mean fluorescence intensity of various hematopoietic (D) and niche (E) cells. (B–E) Means ± SD. *n* = 4; two independent experiments. *, *P* < 0.05; and **, *P* < 0.01 by Tukey's test. (F) Detection of *Clec2* deletion by genomic PCR. An intact exon yields a 2,500-bp product, whereas removal of floxed exon 1 results in a 1,200-bp product. (G) Expression of CLEC-2 in platelets and LT-HSCs from *Clec2^{Mkd/Δ}* (Δ/Δ) and *Clec2^{+/+}* (+/+) mice. Red, CLEC-2 antibody-stained; blue, isotype control. Means ± SD. *n* = 5; two independent experiments. *P* = 0.0078 for platelets and *P* = 0.69 for LT-HSCs by Student's *t* test. (H) IHC of BM staining CLEC-2 and VE-cadherin in *Clec2^{Mkd/Δ}* (Δ/Δ) mice. Bars: (A and H) 100 μm; (A, top right) 25 μm. (I) Measurement of PB parameters in *Clec2^{Mkd/Δ}* (Δ/Δ) and *Clec2^{+/+}* (+/+) mice. Means ± SD. *n* = 5; three independent experiments. *P*-values as indicated by Student's *t* test.

Transcript expression of CLEC-2 signaling pathway genes were decreased in CLEC-2-deficient Mks (Fig. 3 F). To confirm that CLEC-2 signaling affected Thpo production in Mks, we used inducible shRNAs to knock down three downstream molecules involved in CLEC-2 signaling: *Syk*, *Lcp2*, and *Plcg2* (Suzuki-Inoue et al., 2011). Cultured LT-HSCs were transduced with lentiviral clones that inducibly express each shRNA and then cultured to obtain CD41⁺Ter119⁺ Mks. Knockdown of *Syk*, *Lcp2*, and *Plcg2* was highly efficient: transcripts of the targeted genes were nearly absent in sorted Mks (not depicted). Knockdown of *Syk*, *Lcp2*, or *Plcg2* significantly decreased the expression of Thpo in the sorted Mks (Fig. 3 G). These data confirmed that CLEC-2 signaling is indeed critical for Thpo production in Mks.

CLEC-2 deficiency in Mks directly affects HSC cycle quiescence

Because CLEC-2-deficient Mks exhibited diminished Thpo production and could not support cultured HSCs, we next assessed whether HSCs in *Clec2^{Mkd/Δ}* mice were affected in vivo. Lineage and HSPC differentiation were unchanged in the BM of *Clec2^{Mkd/Δ}* mice (Fig. 4, A–C). Functionally, HSPCs from *Clec2^{Mkd/Δ}* mice displayed a significant eleva-

tion in colony-forming capacity, indicating an increase in the proliferation capacity of HSPCs (Fig. 4, D and E). Cell cycle analysis of HSCs, as assessed by Pyronin Y staining, indicated loss of HSC quiescence (Pyronin Y-negative CD34⁺ LSK cells) in *Clec2^{Mkd/Δ}* mice (Fig. 4, F and G). c-Mpl expression was significantly up-regulated in LT-HSCs from *Clec2^{Mkd/Δ}* mice, suggestive of deficient Thpo signaling (Fig. 4 H). Loss of nonhematopoietic niche cells (FCs, MSCs, and OBLs) was not observed in BM of *Clec2^{Mkd/Δ}* mice (Fig. 4, I and J).

Although CLEC-2 is also expressed on ECs, EC-specific CLEC-2 deletion did not alter hematopoiesis: *VE-cadherin-Cre:Clec2^{loxod/floxod}* mice exhibited no change in peripheral blood (PB) parameters (not depicted), HSPC numbers, HSC quiescence, or repopulation potential (not depicted). These observations indicate that Mk-specific *Clec2* deficiency stimulates HSCs to exit the G₀ phase of the cell cycle.

HSCs from *Clec2^{Mkd/Δ}* mice exhibit reduced stem cell potential

To further investigate the stem cell potential of HSCs from *Clec2^{Mkd/Δ}* mice, we performed a competitive repopulation assay, using BM transplantation (BMT) of LT-HSCs from *Clec2^{+/+}* or *Clec2^{Mkd/Δ}* mice (Ly5.2) into C57BL/6-Ly5.1




Figure 2. Altered distribution of Mks in BM of *Clec2^{MkΔ/Δ}* mice. (A and B) Representative flow cytometric plots showing Mk progenitor cell population (MkP: Lin⁻cKit⁺Sca-1⁺[LKS⁻]CD150⁺CD41⁺; Pre-MegE: LKS⁻FcγR⁻CD105⁺CD150⁺) in *Clec2^{MkΔ/Δ}* (Δ/Δ) and *Clec2^{+/+}* (+/+) mice. (C-E) Number of MkP (C), Pre-MegE (D), and CD41⁺ Mks (E) in Δ/Δ and +/+ mice. Means ± SD. *n* = 5; two independent experiments. ns, *P* = 0.46 for C, *P* = 0.24 for D, and *P* = 0.24 for E by Student's *t* test. (F and G) Representative flow cytometric plot showing Mks (F) and Mk frequency within the total Mk population (G), based on ploidy analysis of +/+ and Δ/Δ mice. Means ± SD. *n* = 4; two independent experiments. *, *P* < 0.05 by Tukey's test. (H) IHC of BM, staining for ECs (VE-cadherin), Mks (CD41), and DAPI in the metaphysis and diaphysis of +/+ and Δ/Δ mice. Bar, 100 μm.

recipients. HSCs from *Clec2^{MkΔ/Δ}* mice had lower engraftment rates, as assessed by chimerism in PB and BM of various HSPC fractions 4 mo after primary and secondary BM1 (Fig. 5, A–D). No significant difference was noted in the lineage differentiation of engrafted HSCs from *Clec2^{+/+}* or *Clec2^{MkΔ/Δ}* mice (Fig. 5 E). Limiting dilution analysis revealed a significantly lower frequency of repopulating HSCs in the BM of *Clec2^{MkΔ/Δ}* mice (Fig. 5 F). HSCs from *Clec2^{MkΔ/Δ}* mice did not exhibit defective homing to the BM (Fig. 5 G). In addition, HSCs from *Clec2^{MkΔ/Δ}* mice did not exhibit higher rates of apoptosis, as assessed by Annexin V staining (Fig. 5 H). Gene set enrichment analysis of LT-HSCs from *Clec2^{MkΔ/Δ}* mice revealed altered HSC-related gene expression profiles, notably an enrichment in progenitor cell-related genes, relative to LT-HSCs from *Clec2^{+/+}* mice, suggesting

enhanced differentiation and a loss of stem cell character of HSCs from *Clec2^{MkΔ/Δ}* mice (Fig. 5 I). These results indicate a loss of stem cell potential in *Clec2^{MkΔ/Δ}* mice.

Clec2^{MkΔ/Δ} mice have major developmental vascular defects, chiefly in the lymphatic system (Suzuki-Inoue et al., 2010; Finney et al., 2012). To verify that the loss of stem cell potential resulted specifically from *Clec2* deletion in BM Mk lineages, we transplanted BM mononuclear cells (MNCs) from *Clec2^{+/+}* or *Clec2^{MkΔ/Δ}* mice (Ly5.2) along with BM MNCs from Ly5.1 mice at a 4:1 ratio into lethally irradiated Ly5.1 wild-type mice to test the effect of *Clec2*-deleted Mks on wild-type HSCs (Fig. 6 A). We observed a high frequency of Ly5.2⁺ Mks in recipient BM (Fig. 6 B). The number of engrafted Ly5.1 LT-HSCs (CD34⁺Flt-3⁻ HSCs and CD150⁺CD48⁻CD41⁻ [SLAMF] HSCs) was significantly lower




Figure 3. CLEC-2-positive Mks produce Thpo. (A and B) Effect of 3 d of co-culture with Mks from Δ/Δ or $+/+$ mice on LSK cells (A) and LT-HSCs (B). Means \pm SD. $n = 4$; two independent experiments. *, $P < 0.05$ by Tukey's test. (C) Relative levels of niche factor (*Thpo*, *Angpt1*, *Cxcl12*, *Kitl*, *Il-7*, *Vcam1*, *Spp1*, *Tnfr*, *Tgf-b1*, *Tgf-b2*, *Tgf-b3*, *Fgf1*, and *Pf4*) transcripts in Mks from Δ/Δ mice compared with $+/+$ mice. (D) Relative levels of *Thpo* transcripts were significantly up-regulated in cultured Mks treated with a CLEC-2 stimulatory antibody. (E) IHC of BM from $+/+$ and Δ/Δ mice. Mks, which are CD41, exhibit lower *Thpo* levels in CLEC-2-deficient Mks. Magnification of a representative Mk is shown in the bottom panels. Bars: (top) 50 μ m; (bottom) 100 μ m. (F) Gene expression of CLEC-2 downstream pathway molecules in Mks from $+/+$ and Δ/Δ mice. (G) Knockdown of *Syk*, *Lcp2*, and *Plcg2* results in reduced expression of *Thpo* transcript in Mks. (C, D, F, and G) Means \pm SD. $n = 4$; two independent experiments. ns, $P > 0.05$; *, $P < 0.05$; and **, $P < 0.01$ by Student's *t* test.

in transplants from *Clec2^{Mkd/Δ}* mouse donors (Fig. 6 C). Furthermore, the percentage of Ly5.1⁺ Pyronin Y-negative HSCs was significantly lower when *Clec2^{Mkd/Δ}* mice served as donors (Fig. 6, D and E). Also, both Ly5.1⁺ and Ly5.2⁺ HSCs in the recipient of *Clec2^{Mkd/Δ}* mouse donors stained higher levels of Ki67 (Fig. 6 F), indicating loss of cell cycle quiescence. These data suggest that the HSC defects exhibited by *Clec2^{Mkd/Δ}* mice are a direct consequence of *Clec2* depletion in Mks.

Mk-specific CLEC-2 depletion results in extramedullary hematopoiesis

We next asked whether CLEC-2 deficiency affected HSC retention in the BM. *Clec2^{Mkd/Δ}* mice exhibited massive splenomegaly (Fig. 7, A and B). Both HSC and HSPC number and frequency were elevated in *Clec2^{Mkd/Δ}* mice (Fig. 7, C–E), indicating that the splenomegaly was caused by extramedullary hematopoiesis. PB of HSC *Clec2^{Mkd/Δ}* mice exhibited increased numbers of LSKs and LT-HSCs (Fig. 7 F). Furthermore, a significant increase in CFU-C and HPC-CFC was observed in the PB of *Clec2^{Mkd/Δ}* mice (Fig. 7, G and I), and the distance between LT-HSCs and Mks was significantly higher in *Clec2^{Mkd/Δ}* mice than in *Clec2^{+/+}* mice (Fig. 7 J). These data show that chronic loss of CLEC-2-expressing

Mks decreased HSC retention in BM and induced extramedullary hematopoiesis in the spleen.

Administration of Thpo rescues HSC phenotypes in *Clec2^{Mkd/Δ}* mice

To determine whether the functional defects in HSCs from *Clec2^{Mkd/Δ}* mice could be attributed to reduced Thpo levels, we administered recombinant Thpo (PEG-rHuMGDF) to both *Clec2^{+/+}* and *Clec2^{Mkd/Δ}* mice. Intravenous Thpo injection for four consecutive days restored the number and frequency of polyploid Mks in *Clec2^{Mkd/Δ}* mice (Fig. 8 A). In agreement with a previous study (Walter et al., 2015), administration of Thpo stimulated proliferation of HSCs, as shown by the increased percentage of BrdU-positive HSCs and the percentage of Pyronin Y-negative cells in CD34-LSK cells in both *Clec2^{+/+}* and *Clec2^{Mkd/Δ}* mice (Fig. 8, B and C). However, as Thpo administration instigates self-renewal of HSCs, the absolute number and frequency of CD34⁺ Pyronin Y-negative HSCs within the BM were restored (Fig. 8, D and E). Thpo administration also significantly increased the number of Mks within the BM in both *Clec2^{+/+}* and *Clec2^{Mkd/Δ}* mice (Fig. 8 F). The repopulation potential of HSCs from *Clec2^{Mkd/Δ}* mice significantly increased with Thpo injection, as confirmed by competitive BMT (Fig. 8, G and H). Thus,




Figure 4. HSCs from *Clec2^{MkΔ/Δ}* mice exhibit reduced stem cell quiescence. (A–C) Number of BM MNCs (A), lineage composition in the BM (B), and relative number of BM HSPCs (C) in +/+ and Δ/Δ mice. (D and E) CFU-C number (D) and HPP-CFC number (E) of 500 HSCs from Δ/Δ and +/+ mice. (A–E) Means ± SD. *n* = 6; two independent experiments. ns, *P* > 0.05; and *, *P* < 0.05 by Student's *t* test. (F) Cell cycle analysis using Pyronin Y and Hoechst 33342 staining of CD34⁺ LSK cells in +/+ and Δ/Δ mice. (G) Cell cycle state of CD34⁺ LSK cells with Pyronin Y staining in +/+ and Δ/Δ mice. (H) Relative levels of *Mpl* transcripts in LT-HSCs from +/+ and Δ/Δ mice. (I and J) Number (I) and frequency (J) of ECs (CD45⁺Ter119⁺CD31⁺), MSCs (CD45⁺Ter119⁺Sca-1⁺ALCAM⁺), and OBLs (CD45⁺Ter119⁺CD31⁺Sca-1⁺ALCAM⁺) in Δ/Δ and +/+ mice. (F–J) Means ± SD. *n* = 4; two independent experiments. ns, *P* > 0.05; *, *P* < 0.05; and **, *P* < 0.01 by Student's *t* test.

the loss of HSC potential in *Clec2^{MkΔ/Δ}* mice depended on the defective Thpo production of Mks.

DISCUSSION

In this study, we characterized the niche function of a C-type lectin-like family member, CLEC-2, in Mks. Mks from *Clec2^{MkΔ/Δ}* mice exhibited reduced Thpo expression at both the gene and protein level. Knockdown of the CLEC-2 downstream pathway affected the expression of a broad range of niche factors in Mks, characteristically one being Thpo. Mk-specific deletion of CLEC-2 caused a subtle reduction in Mk number but significantly affected HSC quiescence and repopulation potentials. Administration of recombinant Thpo rescued HSC defects in *Clec2^{MkΔ/Δ}* mice, indicating that defective Thpo production impaired HSC function in *Clec2^{MkΔ/Δ}* mice. Thus, we demonstrated that CLEC-2 is an upstream factor essential for Mk-mediated maintenance of HSCs.

Our results identify Mk CLEC-2 signaling as a novel signaling pathway involved in the production of Thpo in the BM. Systemic Thpo levels depend on sequestration of Thpo by myeloproliferative leukemia protein (c-Mpl), a Thpo

receptor, expressed on platelets (Kuter and Rosenberg, 1995). However, Mks in *Clec2^{MkΔ/Δ}* mice produced lower levels of Thpo, despite the presence of thrombocytopenia, indicating that systemic Thpo levels determined by the availability of c-Mpl did not affect Mk-produced Thpo for the maintenance of HSCs. It remains controversial whether liver production of Thpo can compensate for reduced systemic levels of this cytokine (McCarty et al., 1995; Qian et al., 1998). *Thpo* transcript levels in the liver increase with inflammatory stress and accumulation of desialylated platelets (Wolber et al., 2001; Grozovsky et al., 2015) but does not change in thrombocytopenic mouse models (Cohen-Solal et al., 1996). *Clec2^{MkΔ/Δ}* mice exhibited no change in liver *Thpo* transcript levels (unpublished data), indicating that CLEC-2 deficiency did not stimulate liver Thpo production. Therefore, our data indicate that the BM Thpo level is loosely associated with serum and liver Thpo levels and that Mks supply a critical amount of Thpo for maintenance of HSCs in the BM. However, our data do not eliminate the possibility that Thpo production by the BM stroma is necessary to maintain HSCs in the BM. In fact, OBLs produce Thpo (Yoshihara




Figure 5. HSCs from *Clec2*^{MkdΔ/Δ} mice exhibit reduced repopulation capacity. (A and C) Percentage of donor-derived cells (Ly5.2) in PB after the first and second BMT at the indicated time intervals (in months). (B and D) Percentage of donor-derived cells (Ly5.2) in BM HSPCs after the first and second BMT at the indicated time intervals (in months). (A–D) Means ± SEM. *n* = 6; two independent experiments. *, *P* < 0.05; and **, *P* < 0.01 by Student's *t* test. (E) Lineage composition of Ly5.2 MNCs in recipient mice. Means ± SEM. *n* = 6; two independent experiments. *P* > 0.05 in all groups by Student's *t* test. (F) Extreme limiting dilution assay of BM MNCs from Δ/Δ and +/+ mice. *n* = 7; two independent experiments. *P* = 0.0432 by Pearson's χ^2 test. (G) Number of CFSE⁺ HSC number (X10⁶) from Δ/Δ and +/+ mice homing to the BM 24 h after BMT. Note that no significant difference was present in homing capacity of HSCs from Δ/Δ and +/+ mice. (H) Number of Annexin V⁺ HSCs in Δ/Δ and +/+ mice. (G and H) Means ± SD. *n* = 4; two independent experiments. ns, *P* = 0.677 (G) or *P* = 0.48 (H) by Student's *t* test. (I) Gene set enrichment analysis of LT-HSCs from Δ/Δ and +/+ mice (*n* = 10). Genes expressed by intermediate and multipotent progenitors were significantly up-regulated in LT-HSCs from Δ/Δ mice (plots are second and third from left). Statistical analysis is as shown in figure.

et al., 2007), and the platelet α -granule proteins PDGF and FGF-2 can stimulate expression of Thpo in BM stromal cells in vitro (Sungaran et al., 2000). Further studies are necessary to clarify the degree to which HSCs rely on locally or systemically produced Thpo.

Although HSCs from *Clec2*^{MkdΔ/Δ} mice were responsive to exogenous Thpo, indicating that the loss of stem cell potential of HSCs in *Clec2*^{MkdΔ/Δ} mice was caused by deficiency of Thpo, our data cannot differentiate whether Thpo directly or indirectly affected HSCs through the modulation of Mk number and function. Indeed, exogenous Thpo administration

robustly enhances Mk proliferation and Mks can produce various factors other than Thpo that can affect HSC stem cell potential (Brunts et al., 2014; Zhao et al., 2014). Supporting this, although our analysis revealed Thpo as a prominent niche factor affected by CLEC-2 depletion, CLEC-2 deficiency also affected other niche-related gene expressions (such as *Cxcl12*, *Angpt1*, *Vcam1*, and *Pf4*) in Mks. In addition, CLEC-2-deficient Mks exhibited decrease in various CLEC-2 downstream pathways. These data may indicate that CLEC-2 signaling may be involved in the modulation of a broad range of Mk functions. Our data further position Mks




Figure 6. Loss of HSC quiescence in HSCs in *Clec2^{MkΔ/Δ}* mice is Mk specific. (A) Scheme of the experimental model for BMT. 8×10^6 BM MNCs from Δ/Δ and +/+ mice were transplanted into lethally irradiated (Ly5.1) mice along with Ly5.1-positive 2×10^6 BM MNCs. (B) Percentage of Ly5.2-positive Mks in BMs of recipient mice. (C) Relative number of Ly5.1-positive HSPCs in recipient mice. (B and C) Means \pm SD. $n = 10$; two independent experiments. ns, $P = 0.167$; *, $P < 0.05$; and **, $P < 0.01$ by Student's t test. (D) Ly5.1⁺ Pyronin Y-negative cells in CD34⁺ LSK cells in the BMs of recipient mice. (E) Ly5.1⁺ Pyronin Y-negative cells in CD34⁺ LSK cells in the BMs of recipient mice. (D and E) Means \pm SD. $n = 5$; two independent experiments. **, $P < 0.01$ by Student's t test. (F) Ratio of fluorescence intensity of Ki67 and TOTO-3 on single sorted cells in Ly5.1⁺ or Ly5.2⁺ HSCs in chimeric mice. Means \pm SEM. $n = 50$; two independent experiments. **, $P < 0.01$ by Student's t test.

as a potent niche cell but emphasize the need to elucidate the complex niche regulation on HSCs exerted by Mks.

Recent studies showed that specific depletion of Mks disrupts HSC quiescence through different mechanisms. Induced depletion of Mks for 7 d in *PF4-Cre;iDTR* mice chronically activates HSCs to proliferate and self-renew, through either platelet factor 4 (PF4; Bruns et al., 2014) or transforming growth factor- β 1 (TGF- β 1; Zhao et al., 2014). In contrast, we showed that acute depletion of Mks in *PF4-Cre;iMos-Csp* mice resulted in disruption of HSC quiescence and repopulation potentials without HSC self-renewal (Nakamura-Ishizu et al., 2014b). These three studies all reported direct Mk regulation of HSCs, yet portrayed Mks as acting in different modes, according to the time point after induction of Mk deletion. Confusing matters further, Mk depletion affected different subsets of HSCs in conflicting ways: CD34⁺Flt3⁺LSK cells exhibit modest or no increase in number, whereas CD150⁺CD105⁺LSK cells expanded up to 15-fold (Bruns et al., 2014; Zhao et al., 2014). The differences in the HSC niche functions of Mks may be attributed to the fact that depletion of Mks and platelets dramatically changes the levels of multiple factors. CLEC-2 depletion in Mks did not instigate self-renewal of HSCs or significant changes in platelet lineage-biased CD150⁺CD105⁺LSK cells (Pronk et al., 2007; unpublished data), but it did reduce the stem cell potential of LT-HSCs (CD34⁺Flt3⁺LSK; Christensen and Weissman, 2001). Our study indicates that CLEC-2-mediated Mk regulation of HSCs is not committed to the self-renewal of Mk lineage-biased HSCs, but instead specifically influences the quiescence and stem cell potential of a broader

spectrum of HSCs. CLEC-2 may be an Mk-specific niche regulatory factor that shows the long-term effect of Mk regulation on HSC maintenance.

Constitutive deletion of CLEC-2 and conditional deletion of CLEC-2 from Mk/platelet lineages reportedly results in blood and lymphatic vessel dis-separation phenotype (Bertozzi et al., 2010; Suzuki-Inoue et al., 2010). Recently, the role of CLEC-2 in lymph node development and adult lymph node maintenance was reported (Herzog et al., 2013; Bénézech et al., 2014). Chimeric mice in which BMs of WT mice were reconstituted with BMs from *Clec2^{MkΔ/Δ}* mice have been reported to present hemorrhage in the lymph nodes, indicating that platelet CLEC-2 maintains the integrity of vessels in the adult lymph node. No apparent hemorrhages in the lymph nodes were observed in the chimeric mice in which BMs of *Clec2^{MkΔ/Δ}* mice and *Clec2^{+/+}* mice was transplanted in a 4:1 ratio, presumably because of the mixture of *Clec2^{+/+}* mouse-derived BM (unpublished data). The gross morphology of vasculature in the BM was unaffected in *Clec2^{MkΔ/Δ}* mice, and no hemorrhage was observed in the BMs (unpublished data). Moreover, EC-specific deletion of CLEC-2 did not affect hematopoiesis. However, whether deficiency of CLEC-2 in platelets affected the function of BM ECs, especially in association to immune response, should be investigated in the future.

A characteristic finding in the *Clec2^{MkΔ/Δ}* mice was the presence of extramedullary hematopoiesis. Thpo is known as a cytokine to induce HSC mobilization (Murray et al., 1998). Accordingly, administration of exogenous Thpo to *Clec2^{MkΔ/Δ}* mice increased mobilization of HSCs to PB and




Figure 7. *Clec2^{MkdΔ/Δ}* mice exhibit extramedullary hematopoiesis and elevated mobilization of HSCs into PB. (A and B) Gross appearance (A) and hematoxylin and eosin staining (B) of spleens from +/+ and Δ/Δ mice. Arrowheads indicate the presence of Mks in *Clec2^{Mkd+/+}* spleens. Magnification of an Mk is shown in the inset. Bar, 200 μm. (C–E) Analysis of spleen of Δ/Δ and +/+ mice. Spleen weight (C), total MNC number (D), and absolute populations of various HSPC fractions (E) are significantly higher in spleens of *Clec2^{MkdΔ/Δ}* compared with *Clec2^{Mkd+/+}* mice. (F–H) Percentage of LSK cells (F), CFU-C number (G), and HPP-CFC number (H) in PB of +/+ and Δ/Δ mice. (C–H) Means ± SD. *n* = 6; two independent experiments. **, *P* < 0.01 by Student's *t* test. (I) Quantitation of distance of LT-HSCs from Mks in +/+ and Δ/Δ mice. Means ± SD. *n* = 6; two independent experiments. *, *P* = 0.038 by Tukey's test.

did not rescue the extramedullary hematopoiesis phenotype. Therefore, decreased levels of Thpo in *Clec2^{MkdΔ/Δ}* mice are not causative of the extramedullary hematopoiesis phenotype. The mechanism of how Mks retain HSCs within the BM and how CLEC-2 signaling associates with HSC retention is yet to be investigated.

Mks indirectly regulate HSCs by stimulating OBLs after transplantation (Olson et al., 2013). Mk numbers in *Clec2^{MkdΔ/Δ}* mice were reduced preferentially in the metaphyseal region of the BM. Podoplanin, an activating ligand of CLEC-2 (Bertozzi et al., 2010), was highly expressed in osteo-lineage cells (Schacht et al., 2005). Displacement of Mks in *Clec2^{MkdΔ/Δ}* mice from the bone-rich metaphysis suggests that CLEC-2 deficiency in Mks may impair Mk and OBL interactions. Furthermore, it indicates that OBLs may indirectly regulate Thpo production in Mks via their expression of podoplanin. Moreover, our findings suggest that CLEC-2–podoplanin signaling may be a novel molecular pathway for niche cell function. Indeed, CLEC-2–deficient Mks exhibited decreased gene expression of CLEC-2 downstream molecules, and knockdown of signals downstream of the CLEC-2–podoplanin interaction (*Syk*, *Lcp2*, and *Plcg2*) confirmed that CLEC-2 signaling is crucial for Mk Thpo production. Loss of sialic acid expression on platelets con-

tributes to Thpo production in the liver (Grozovsky et al., 2015). Because the lectin-like properties of CLEC-2 allow it to interact with sialic acid residues on podoplanin (Pan et al., 2014), our findings provide insight into the involvement of glycosylation in Thpo production.

In summary, our study strongly indicates that Mks function as a niche to maintain HSC quiescence through CLEC-2. These findings could enable manipulation of HSCs and Mks for clinical applications, as well as therapies against diseases related to defects in HSCs and Mks.

MATERIALS AND METHODS

Mice. All mice were in the C57BL/6 background. *Clec2^{fllox/fllox}* mice were described previously (Osada et al., 2012). *PF4-Cre* transgenic mice were provided by R.C. Skoda (University Hospital, Basel, Switzerland; Tiedt et al., 2007). *Clec2^{fllox/fllox}* mice were crossed with either *PF4-Cre* or *VE-cadherin-Cre* (*VEC-Cre*) transgenic mice (stock 006137 purchased from The Jackson Laboratory) to obtain *PF4-Cre:Clec2^{fllox/fllox}* mice (*Clec2^{MkdΔ/Δ}*) or *VEC-Cre:Clec2^{fllox/fllox}* mice (*Clec2^{ECΔ/Δ}*), respectively. C57BL/6-Ly5.1 or C57BL/6-Ly5.2 mice were used for competitive repopulation assays. Unless specified, 10–12-wk-old mice were used in all experiments. All animal experiments were approved by Keio University and performed




Figure 8. Maintenance of HSC quiescence requires Thpo produced by CLEC-2-positive Mks. (A) Changes in Mk number based on ploidy analysis after intravenous Thpo injection in *Clec2^{MHAΔ}* (Δ/Δ) and *Clec2^{Mk+/+}* ($+/+$) mice. Controls were injected with PBS. (B) Change in percentage of BrdU-positive HSCs after intravenous Thpo injection in Δ/Δ and $+/+$ mice. (A and B) Means \pm SD. $n = 4$ (B) or 5 (A); two independent experiments. **, $P < 0.01$ by Tukey's test. (C) Representative flow cytometry plot of Pyronin Y and Hoechst 33342 for CD34-LSK cells from Δ/Δ and $+/+$ mice after administration of PBS or Thpo. Numbers indicate percentage of Pyronin Y-negative cells in CD34-LSK cells. Means \pm SD. $n = 4$; two independent experiments. *, $P < 0.05$ by Student's t test. (D and E) Total number (D) and frequency (E) of Pyronin Y-negative CD34-LSK cells. Means \pm SD. $n = 4$; two independent experiments. **, $P < 0.01$ by Tukey's test. Note that Pyronin Y-negative CD34-LSK cell number is restored in *Clec2^{MHAΔ}* (Δ/Δ) BM after Thpo injection. (F) IHC of BMs from Δ/Δ and $+/+$ mice after administration of PBS or Thpo. Bar, 100 μ m. (G and H) Percentage of donor-derived cells in PB (G) and BM HSPCs (H) at the indicated intervals after BMT. Means \pm SEM. $n = 6$; two independent experiments. *, $P < 0.05$; and **, $P < 0.01$ by Tukey's test.

in accordance with the Guidelines of Keio University for Animal and Recombinant DNA experiments.

PB analysis and colony assays. PB was collected from the tail vein in a heparinized microtube (Drummond Scientific) and analyzed using CellTac (NIHON KOHDEN). For colony assays and assessment of PB mobilization of HSCs, PB was collected from the inferior vena cava of anesthetized mice using a 27G needle. MNCs from 0.5 ml PB were obtained by centrifugation using Lymphoprep (Axis-Shield) and then used for colony assays. Colony counts for CFU-C and HPP-CFC were assessed on days 7 and 14, respectively.

Antibodies. Primary antibodies used for IHC and flow cytometry were as follows: c-Kit (2B8; eBioscience), CD16/32 (93; eBioscience), VE-cadherin (eBioscience), c-Kit (R&D Systems), Sca-1 (E13-161.7; BioLegend), CD48 (HM48-1; BioLegend), CD150 (TC15-12F12.2; BioLegend), IL-7R α (SB/199; BioLegend), endoglin (MJ7/18; BioLegend), CD4 (L3T4; BD), CD8 (53-6.72; BD), B220 (RA3-6B2; BD),

TER-119 (BD), Gr-1 (RB6-8C5; BD), CD34 (RAM34; BD), Mac-1 (M/70; BD), Flt-3 (A2F10.1; BD), CD41 (MWReg30; BD), CD45.2 (104; BD), CD45.1 (A20; BD), GPIIb α (Xia. G5; Emfret), Clec2 (AbD Serotec), and Thpo (Bioss). Secondary antibodies for IHC were Alexa Fluor 488-conjugated IgGs (Molecular Probes) or Cy3/Cy5/DyLight549/DyLight649-conjugated IgGs (Jackson ImmunoResearch Laboratories, Inc.). IHC specimens were treated with DAPI (Molecular Probes) for nuclear staining. Stimulatory rabbit anti-mouse CLEC-2 antibody was a gift of K. Suzuki-Inoue.

Immunostaining of BM. Decalcified BM sections were prepared and stained as described previously (Nakamura-Ishizu et al., 2012). Frozen sections prepared according to the Kawamoto method (Kawamoto, 2003) were used to stain Lin⁻CD41⁻CD48⁺CD150⁺ cells in the BM.

Confocal microscopy and quantification of fluorescent images. Fluorescence images were obtained using a confocal laser-scanning microscope (FV1000; Olympus). Scanning

was performed in sequential laser emission mode to avoid scanning at other wavelengths. Images obtained from BM sections were analyzed using the TissueQuest image analysis software (TissueGnostics).

Flow cytometric analysis, cell cycle analysis, and competitive repopulation assays. Flow cytometric analysis and competitive repopulation assays were performed as described previously (Arai et al., 2004). Cell cycle analysis of hematopoietic cells was performed using Pylonin Y staining and short-term BrdU incorporation assays (Takubo et al., 2010). For Ki-67 staining, HSCs were sorted and attached to glass slides with sedimentation and subsequently stained for Ki-67 and TOTO-3. Cells were observed under a confocal laser-scanning microscope (FV1000) for measurement of single cell fluorescence intensity and calculated for their relative Ki-67 fluorescence against nuclear stain (TOTO-3).

BMT. BM MNCs (4×10^5 cells) from C57BL/6-Ly5.1 mice, together with LT-HSCs (5×10^2 cells) from the indicated mice (Ly5.2), were transplanted into lethally irradiated C57BL/6-Ly5.1 congenic mice. Secondary transplantations into lethally irradiated C57BL/6-Ly5.1 congenic mice were performed using 2×10^6 BM MNCs from primary recipients. Recipient mice were sacrificed for analysis 4 mo after BMT. For extreme limiting dilution assays (Hu and Smyth, 2009), lethally irradiated Ly5.1 mice were transplanted with 10^4 , 2×10^4 , or 3×10^4 BM MNCs from either *Clec2^{+/+}* or *Clec2^{Mh4/4}* mice along with 2×10^5 Ly5.1 competitor cells. PB chimerism for the limiting dilution assay was assessed 12 wk after transplantation.

In vitro HSC and Mk co-cultures. Mature Mks (B220⁻Mac-1⁻Gr-1⁻CD41⁺) were obtained from mouse BM as described previously (Heazlewood et al., 2013). LT-HSCs (Lin⁻c-Kit⁺Sca-1⁺Flt-3⁻CD34⁺) sorted from Ly5.1 mice were co-cultured for 3 d with Mks in SF-O3 medium (San-kyo Junyaku) supplemented with murine recombinant SCF (100 ng/ml) with or without human recombinant Thpo (100 ng/ml) and then analyzed (Kabaya et al., 1996). LT-HSCs and Mks were cultured at a 1:1 ratio. Mks were cultured for 2 d to obtain conditioned medium for the indicated experiments. To inhibit Thpo activity, a recombinant mouse ThpoR (Mpl) Fc chimera (0.4 μ g/ml; R&D Systems) was added to the culture. An IgG Fc fragment (0.4 μ g/ml; Jackson ImmunoResearch Laboratories, Inc.) served as a control. For knockdowns in Mks, MISSION custom vectors (Sigma-Aldrich) were used.

In vivo Thpo assays. For in vivo stimulation of Thpo signaling, recombinant human Thpo (PEG-rHuMGDF; Kabaya et al., 1996; donated by Kyowa Hakko Kirin Co., Ltd.) was administered. Mice were treated with either 100 μ g/kg (i.v.) of PEG-rHuMGDF or human IgG Fc fragment (Jackson ImmunoResearch Laboratories, Inc.). For rescue experiments, *Clec2^{Mh4/4}* mice were treated for four consecutive days.

Quantitative PCR assay. Isolated RNA was reverse transcribed with Superscript VILO (Invitrogen). Quantitative PCR assays were performed using an ABI 7500 Fast Real-Time PCR System (Applied Biosystems), SYBR Premix Ex Taq (Takara Bio Inc.), and primer sets for each gene (Takara Bio Inc.). Values obtained were normalized to β -actin expression and expressed as fold induction relative to control samples.

Genomic PCR assay. Genomic DNA was isolated from sorted cells using NucleoSpin (Takara Bio Inc.), and PCR was conducted using 5'-ACGTATCTCTGAA CATCCAAGAAAG-3' and 5'-CTGATCTTACCTG CATTCCATTAGT-3' as primers.

Gene set enrichment analysis. Total RNA was extracted from LT-HSCs (Lin⁻cKit⁺Sca-1⁺CD34⁺Flt-3⁻) from *Clec2^{Mh4/4}* and *Clec2^{+/+}* mice. Total RNA was purified using an RNeasy Mini kit (QIAGEN). Microarray processing was performed by DNA Chip Research Inc. Normalized expression data were assessed using GSEA v2.0.13 software (Broad Institute). Gene sets used were PARK_HSC_VS_MULTIPOTENT_PROGENITORS_DN, PARK_HSC_VS_MULTIPOTENT_PROGENITORS_UP, PARK_HSC_MARKER, PARK_HSC_AND_MULTIPOTENT_PROGENITORS, IVANOVA_HEMATOPOIESIS_STEM_CELL, GRAHAM_CML QUIESCENT_VS_NORMAL QUIESCENT_UP, GRAHAM_NORMAL QUIESCENT_VS_NORMAL_DIVIDING_UP, BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_TRANS, BAKKER_FOXO3_TARGETS_UP, IVANOVA_HEMATOPOIESIS_EARLY_PROGENITOR, IVANOVA_HEMATOPOIESIS_INTERMEDIATE_PROGENITOR, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, IVANOVA_HEMATOPOIESIS_STEM_CELL_LONG_TERM, IVANOVA_HEMATOPOIESIS_STEM_CELL_SHORT_TERM, JAATINEN_HEMATOPOIETIC_STEM_CELL_UP, and JAATINEN_HEMATOPOIETIC_STEM_CELL_DN, obtained from the Molecular Signatures Database v4.0 available at the GSEA website. The number of permutations was set at 1,000. Gene sets with nominal p-value <0.05 and a false discovery rate q-value (FDR-q) <0.25 were considered statistically significant.

Statistical analysis. All results are expressed as means \pm SD unless otherwise specified. Statistical significance was determined by Tukey's multiple comparison test. The two-tailed Student's *t* test was used for two-group comparisons. All experiments were conducted and confirmed in at least two replicates.

ACKNOWLEDGMENTS

The authors thank T. Muraki and T. Hirose for technical assistance.

T. Suda is supported by the National Medical Research Council (NMRC) grant of Singapore Translational Research Investigator (STaR) Award Investigator. A. Nakamura-Ishizu was supported in part by a fellowship from the Japan Society for the Promotion of Science, a Grants-in-Aid for Scientific Research (25-40030 and 26713035), a research grant from the SENSHIN medical research foundation, a research grant

from the Takeda Foundation, and a grant from the Naito Foundation. K. Takubo was supported in part by a Ministry of Education, Culture, Sports, Science and Technology (MEXT) Grant-in-Aid for Young Scientists (A). T. Suda and K. Takubo were supported in part by a MEXT Grant-in-Aid for Scientific Research (A) and a MEXT Grant-in-Aid for Scientific Research on Innovative Areas. K. Suzuki-Inoue was supported in part by the MEXT program (LS052). K. Takubo was supported in part by a MEXT Grant-in-Aid for Scientific Research (15H04861,26115005) and a Grant of the National Center for Global Health and Medicine (H26-001).

The authors declare no competing financial interests.

Author contributions: T. Suda, K. Takubo, and A. Nakamura-Ishizu designed the project, analyzed the data, and wrote the manuscript. A. Nakamura-Ishizu and K. Takubo organized, performed, and analyzed all experiments. H. Kobayashi performed and analyzed the microarray gene expression experiment. K. Suzuki-Inoue provided mice and discussed and analyzed experiments. All authors read and approved the final manuscript.

Submitted: 12 January 2015

Accepted: 2 October 2015

REFERENCES

- Acton, S.E., J.L. Astarita, D. Malhotra, V. Lukacs-Kornek, B. Franz, P.R. Hess, Z. Jakus, M. Kuligowski, A.L. Fletcher, K.G. Elpek, et al. 2012. Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2. *Immunity*. 37:276–289. <http://dx.doi.org/10.1016/j.immuni.2012.05.022>
- Acton, S.E., A.J. Farrugia, J.L. Astarita, D. Mourão-Sá, R.P. Jenkins, E. Nye, S. Hooper, J. van Blijswijk, N.C. Rogers, K.J. Snelgrove, et al. 2014. Dendritic cells control fibroblastic reticular network tension and lymph node expansion. *Nature*. 514:498–502. <http://dx.doi.org/10.1038/nature13814>
- Arai, F., and T. Suda. 2007. Maintenance of quiescent hematopoietic stem cells in the osteoblastic niche. *Ann. N.Y. Acad. Sci.* 1106:41–53. <http://dx.doi.org/10.1196/annals.1392.005>
- Arai, F., A. Hirao, M. Ohmura, H. Sato, S. Matsuoka, K. Takubo, K. Ito, G.Y. Koh, and T. Suda. 2004. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. *Cell*. 118:149–161. <http://dx.doi.org/10.1016/j.cell.2004.07.004>
- Bénézech, C., S. Nayar, B.A. Finney, D.R. Withers, K. Lowe, G.E. Desanti, C.L. Marriott, S.P. Watson, J.H. Caamaño, C.D. Buckley, and F. Barone. 2014. CLEC-2 is required for development and maintenance of lymph nodes. *Blood*. 123:3200–3207. <http://dx.doi.org/10.1182/blood-2013-03-489286>
- Bertozi, C.C., A.A. Schmaier, F. Mericko, P.R. Hess, Z. Zou, M. Chen, C.-Y. Chen, B. Xu, M.-M. Lu, D. Zhou, et al. 2010. Platelets regulate lymphatic vascular development through CLEC-2–SLP-76 signaling. *Blood*. 116:661–670. <http://dx.doi.org/10.1182/blood-2010-02-270876>
- Bruns, I., D. Lucas, S. Pinho, J. Ahmed, M.P. Lambert, Y. Kunisaki, C. Scheiermann, L. Schiff, M. Poncz, A. Bergman, and P.S. Frenette. 2014. Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. *Nat. Med.* 20:1315–1320. <http://dx.doi.org/10.1038/nm.3707>
- Butler, J.M., D.J. Nolan, E.L. Vertes, B. Varnum-Finney, H. Kobayashi, A.T. Hooper, M. Seandel, K. Shido, I.A. White, M. Kobayashi, et al. 2010. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. *Cell Stem Cell*. 6:251–264. <http://dx.doi.org/10.1016/j.stem.2010.02.001>
- Chow, A., D. Lucas, A. Hidalgo, S. Méndez-Ferrer, D. Hashimoto, C. Scheiermann, M. Batista, M. Leboeuf, C. Prophete, N. van Rooijen, et al. 2011. Bone marrow CD169⁺ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. *J. Exp. Med.* 208:261–271. <http://dx.doi.org/10.1084/jem.20101688>
- Christensen, J.L., and I.L. Weissman. 2001. Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. *Proc. Natl. Acad. Sci. USA*. 98:14541–14546. <http://dx.doi.org/10.1073/pnas.261562798>
- Cohen-Solal, K., J.L. Villeval, M. Titeux, S. Lok, W. Vainchenker, and F. Wendling. 1996. Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. *Blood*. 88:2578–2584.
- de Graaf, C.A., M. Kauppi, T. Baldwin, C.D. Hyland, D. Metcalf, T.A. Willson, M.R. Carpinelli, G.K. Smyth, W.S. Alexander, and D.J. Hilton. 2010. Regulation of hematopoietic stem cells by their mature progeny. *Proc. Natl. Acad. Sci. USA*. 107:21689–21694. <http://dx.doi.org/10.1073/pnas.1016166108>
- Ding, L., T.L. Saunders, G. Enikolopov, and S.J. Morrison. 2012. Endothelial and perivascular cells maintain haematopoietic stem cells. *Nature*. 481:457–462. <http://dx.doi.org/10.1038/nature10783>
- Fandrey, J., and H.F. Bunn. 1993. In vivo and in vitro regulation of erythropoietin mRNA: measurement by competitive polymerase chain reaction. *Blood*. 81:617–623.
- Finney, B.A., E. Schweighoffer, L. Navarro-Núñez, C. Bénézech, F. Barone, C.E. Hughes, S.A. Langan, K.L. Lowe, A.Y. Pollitt, D. Mourao-Sa, et al. 2012. CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for development. *Blood*. 119:1747–1756. <http://dx.doi.org/10.1182/blood-2011-09-380709>
- Fujisaki, J., J. Wu, A.L. Carlson, L. Silberstein, P. Putheti, R. Larocca, W. Gao, T.I. Saito, C. Lo Celso, H. Tsuyuzaki, et al. 2011. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. *Nature*. 474:216–219. <http://dx.doi.org/10.1038/nature10160>
- Grozovsky, R., A.J. Begonja, K. Liu, G. Visner, J.H. Hartwig, H. Falet, and K.M. Hoffmeister. 2015. The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. *Nat. Med.* 21:47–54. <http://dx.doi.org/10.1038/nm.3770>
- Heazlewood, S.Y., R.J. Neaves, B. Williams, D.N. Haylock, T.E. Adams, and S.K. Nilsson. 2013. Megakaryocytes co-localise with hemopoietic stem cells and release cytokines that up-regulate stem cell proliferation. *Stem Cell Res (Amst.)*. 11:782–792. <http://dx.doi.org/10.1016/j.scr.2013.05.007>
- Herzog, B.H., J. Fu, S.J. Wilson, P.R. Hess, A. Sen, J.M. McDaniel, Y. Pan, M. Sheng, T. Yago, R. Silasi-Mansat, et al. 2013. Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. *Nature*. 502:105–109. <http://dx.doi.org/10.1038/nature12501>
- Hu, Y., and G.K. Smyth. 2009. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. *J. Immunol. Methods*. 347:70–78. <http://dx.doi.org/10.1016/j.jim.2009.06.008>
- Kabaya, K., H. Akahori, K. Shibuya, Y. Nitta, M. Ida, M. Kusaka, T. Kato, and H. Miyazaki. 1996. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice. *Stem Cells*. 14:651–660. <http://dx.doi.org/10.1002/stem.140651>
- Kaser, A., G. Brandacher, W. Steurer, S. Kaser, F.A. Offner, H. Zoller, I. Theurl, W. Widder, C. Molnar, O. Ludwiczek, et al. 2001. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. *Blood*. 98:2720–2725. <http://dx.doi.org/10.1182/blood.V98.9.2720>
- Katayama, Y., M. Battista, W.-M. Kao, A. Hidalgo, A.J. Peired, S.A. Thomas, and P.S. Frenette. 2006. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. *Cell*. 124:407–421. <http://dx.doi.org/10.1016/j.cell.2005.10.041>
- Kawamoto, T. 2003. Use of a new adhesive film for the preparation of multi-purpose fresh-frozen sections from hard tissues, whole-animals, insects and plants. *Arch. Histol. Cytol.* 66:123–143. <http://dx.doi.org/10.1017/aohc.66.123>
- Kollet, O., A. Dar, S. Shivtuel, A. Kalinkovich, K. Lapid, Y. Sztainberg, M. Tesio, R.M. Samstein, F. Goichberg, A. Spiegel, et al. 2006. Osteoclasts degrade

- endosteal components and promote mobilization of hematopoietic progenitor cells. *Nat Med*. 12:657–664. <http://dx.doi.org/10.1038/nm1417>
- Kuter, D.J., and R.D. Rosenberg. 1995. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. *Blood*. 85:2720–2730.
- McCarty, J.M., K.H. Sprugel, N.E. Fox, D.E. Sabath, and K. Kaushansky. 1995. Murine thrombopoietin mRNA levels are modulated by platelet count. *Blood*. 86:3668–3675.
- Méndez-Ferrer, S., I.V. Michurina, F. Ferraro, A.R. Mazloom, B.D. Macarthur, S.A. Lira, D.T. Scadden, A. Ma'ayan, G.N. Enikolopov, and P.S. Frenette. 2010. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. *Nature*. 466:829–834. <http://dx.doi.org/10.1038/nature09262>
- Murray, L.J., K.M. Luens, M.F. Estrada, E. Bruno, R. Hoffman, R.L. Cohen, M.A. Ashby and S. Vadhan-Raj. 1998. Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis. *Exp. Hematol*. 26:207–216.
- Nakamura-Ishizu, A., Y. Okuno, Y. Omatsu, K. Okabe, J. Morimoto, T. Uede, T. Nagasawa, T. Suda, and Y. Kubota. 2012. Extracellular matrix protein tenascin-C is required in the bone marrow microenvironment primed for hematopoietic regeneration. *Blood*. 119:5429–5437. <http://dx.doi.org/10.1182/blood-2011-11-393645>
- Nakamura-Ishizu, A., H. Takizawa, and T. Suda. 2014a. The analysis, roles and regulation of quiescence in hematopoietic stem cells. *Development*. 141:4656–4666. <http://dx.doi.org/10.1242/dev.106575>
- Nakamura-Ishizu, A., K. Takubo, M. Fujioka, and T. Suda. 2014b. Megakaryocytes are essential for HSC quiescence through the production of thrombopoietin. *Biochem. Biophys. Res. Commun*. 454:353–357. <http://dx.doi.org/10.1016/j.bbrc.2014.10.095>
- Naveiras, O., V. Nardi, P.L. Wenzel, P.V. Hauschka, F. Fahey, and G.Q. Daley. 2009. Bone-marrow adipocytes as negative regulators of the hematopoietic microenvironment. *Nature*. 460:259–263. <http://dx.doi.org/10.1038/nature08099>
- Nomura, S., K. Ogami, K. Kawamura, I. Tsukamoto, Y. Kudo, Y. Kanakura, Y. Kitamura, H. Miyazaki, and T. Kato. 1997. Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization. *Exp. Hematol*. 25:565–572.
- Olson, T.S., A. Caselli, S. Otsuru, T.J. Hofmann, R. Williams, P. Paolucci, M. Dominici, and E.M. Horwitz. 2013. Megakaryocytes promote murine osteoblastic HSC niche expansion and stem cell engraftment after radioablative conditioning. *Blood*. 121:5238–5249. <http://dx.doi.org/10.1182/blood-2012-10-463414>
- Orkin, S.H., and L.I. Zon. 2008. Hematopoiesis: an evolving paradigm for stem cell biology. *Cell*. 132:631–644. <http://dx.doi.org/10.1016/j.cell.2008.01.025>
- Osada, M., O. Inoue, G. Ding, T. Shirai, H. Ichise, K. Hirayama, K. Takano, Y. Yatomi, M. Hirashima, H. Fujii, et al. 2012. Platelet activation receptor CLEC-2 regulates blood/lymphatic vessel separation by inhibiting proliferation, migration, and tube formation of lymphatic endothelial cells. *J. Biol. Chem*. 287:22241–22252. <http://dx.doi.org/10.1074/jbc.M111.329987>
- Pan, Y., T. Yago, J. Fu, B. Herzog, J.M. McDaniel, P. Mehta-D'Souza, X. Cai, C. Ruan, R.P. McEver, C. West, et al. 2014. Podoplanin requires sialylated O-glycans for stable expression on lymphatic endothelial cells and for interaction with platelets. *Blood*. 124:3656–3665. <http://dx.doi.org/10.1182/blood-2014-04-572107>
- Pronk, C.J.H., D.J. Rossi, R. Månsson, J.L. Attema, G.L. Norddahl, C.K.F. Chan, M. Sigvardsson, I.L. Weissman, and D. Bryder. 2007. Elucidation of the phenotypic, functional, and molecular topography of a myeloid progenitor cell hierarchy. *Cell Stem Cell*. 1:428–442. <http://dx.doi.org/10.1016/j.stem.2007.07.005>
- Qian, H., N. Buza-Vidas, C.D. Hyland, C.T. Jensen, J. Antonchuk, R. Månsson, L.A. Thoren, M. Ekblom, W.S. Alexander, and S.E. Jacobsen. 2007. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. *Cell Stem Cell*. 1:671–684. <http://dx.doi.org/10.1016/j.stem.2007.10.008>
- Qian, S., F. Fu, W. Li, Q. Chen, and F.J. de Sauvage. 1998. Primary role of the liver in thrombopoietin production shown by tissue-specific knockout. *Blood*. 92:2189–2191.
- Schacht, V., S.S. Dadras, L.A. Johnson, D.G. Jackson, Y.-K. Hong, and M. Detmar. 2005. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. *Am. J. Pathol*. 166:913–921. [http://dx.doi.org/10.1016/S0002-9440\(10\)62311-5](http://dx.doi.org/10.1016/S0002-9440(10)62311-5)
- Schofield, R. 1978. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. *Blood Cells*. 4:7–25.
- Senis, Y.A., M.G. Tomlinson, A. Garcia, S. Dumon, V.L. Heath, J. Herbert, S.P. Cobbold, J.C. Spalton, S. Ayman, R. Antrobus, et al. 2007. A comprehensive proteomics and genomics analysis reveals novel transmembrane proteins in human platelets and mouse megakaryocytes including G6b-B, a novel immunoreceptor tyrosine-based inhibitory motif protein. *Mol. Cell. Proteomics*. 6:548–564. <http://dx.doi.org/10.1074/mcp.D600007-MCP200>
- Stone, R.L., A.M. Nick, I.A. McNeish, F. Balkwill, H.D. Han, J. Bottsford-Miller, R. Rupaimoole, G.N. Armaiz-Pena, C.V. Pecot, J. Coward, et al. 2012. Paraneoplastic thrombocytosis in ovarian cancer. *N. Engl. J. Med*. 366:610–618. (published erratum appears in *N. Engl. J. Med*. 2012. 367:1768) <http://dx.doi.org/10.1056/NEJMoa1110352>
- Sugiyama, T., H. Kohara, M. Noda, and T. Nagasawa. 2006. Maintenance of the hematopoietic stem cell pool by CXCL12–CXCR4 chemokine signaling in bone marrow stromal cell niches. *Immunity*. 25:977–988. <http://dx.doi.org/10.1016/j.immuni.2006.10.016>
- Sungaran, R., O.T. Chisholm, E. Markovic, L.M. Khachigian, Y. Tanaka, and B.H. Chong. 2000. The role of platelet alpha-granular proteins in the regulation of thrombopoietin messenger RNA expression in human bone marrow stromal cells. *Blood*. 95:3094–3101.
- Suzuki-Inoue, K., G.L.J. Fuller, A. Garcia, J.A. Eble, S. Pohlmann, O. Inoue, T.K. Gartner, S.C. Hughan, A.C. Pearce, G.D. Liang, et al. 2006. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. *Blood*. 107:542–549. <http://dx.doi.org/10.1182/blood-2005-05-1994>
- Suzuki-Inoue, K., Y. Kato, O. Inoue, M.K. Kaneko, K. Mishima, Y. Yatomi, Y. Yamazaki, H. Narimatsu, and Y. Ozaki. 2007. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. *J. Biol. Chem*. 282:25993–26001. <http://dx.doi.org/10.1074/jbc.M702327200>
- Suzuki-Inoue, K., O. Inoue, G. Ding, S. Nishimura, K. Hokamura, K. Eto, H. Kashiwagi, Y. Taniyama, Y. Yatomi, K. Umemura, et al. 2010. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. *J. Biol. Chem*. 285:24494–24507. <http://dx.doi.org/10.1074/jbc.M110.130575>
- Suzuki-Inoue, K., O. Inoue, and Y. Ozaki. 2011. The novel platelet activation receptor CLEC-2. *Platelets*. 22:380–384. <http://dx.doi.org/10.3109/09537104.2011.556274>
- Takubo, K., N. Goda, W. Yamada, H. Iriuchishima, E. Ikeda, Y. Kubota, H. Shima, R.S. Johnson, A. Hirao, M. Suematsu, and T. Suda. 2010. Regulation of the HIF-1 α level is essential for hematopoietic stem cells. *Cell Stem Cell*. 7:391–402. <http://dx.doi.org/10.1016/j.stem.2010.06.020>
- Tiedt, R., T. Schomber, H. Hao-Shen, and R.C. Skoda. 2007. Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. *Blood*. 109:1503–1506. <http://dx.doi.org/10.1182/blood-2006-04-020362>

- Walter, D., A. Lier, A. Geiselhart, F.B. Thalheimer, S. Huntscha, M.C. Sobotta, B. Moehrl, D. Brocks, I. Bayindir, P. Kaschutnig, et al. 2015. Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells. *Nature*. 520:549–552. <http://dx.doi.org/10.1038/nature14131>
- Wolber, E.M., J. Fandrey, U. Frackowski, and W. Jelkmann. 2001. Hepatic thrombopoietin mRNA is increased in acute inflammation. *Thromb. Haemost.* 86:1421–1424.
- Yamazaki, S., H. Ema, G. Karlsson, T. Yamaguchi, H. Miyoshi, S. Shioda, M.M. Taketo, S. Karlsson, A. Iwama, and H. Nakauchi. 2011. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. *Cell*. 147:1146–1158. <http://dx.doi.org/10.1016/j.cell.2011.09.053>
- Yoshihara, H., F. Arai, K. Hosokawa, T. Hagiwara, K. Takubo, Y. Nakamura, Y. Gomei, H. Iwasaki, S. Matsuoka, K. Miyamoto, et al. 2007. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. *Cell Stem Cell*. 1:685–697. <http://dx.doi.org/10.1016/j.stem.2007.10.020>
- Zhao, M., J.M. Perry, H. Marshall, A. Venkatraman, P. Qian, X.C. He, J. Ahamed, and L. Li. 2014. Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. *Nat. Med.* 20:1321–1326. <http://dx.doi.org/10.1038/nm.3706>
- Zucker-Franklin, D., and K. Kaushansky. 1996. Effect of thrombopoietin on the development of megakaryocytes and platelets: an ultrastructural analysis. *Blood*. 88:1632–1638.

RESEARCH ARTICLE

Vascular Smooth Muscle Cells Stimulate Platelets and Facilitate Thrombus Formation through Platelet CLEC-2: Implications in Atherothrombosis

Osamu Inoue¹, Kazuya Hokamura², Toshiaki Shirai¹, Makoto Osada¹, Nagaharu Tsukiji¹, Kinta Hatakeyama³, Kazuo Umemura², Yujiro Asada³, Katsue Suzuki-Inoue^{1*}, Yukio Ozaki¹

1 Department of Clinical and Laboratory Medicine, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi 409–3898, Japan, **2** Department of Pharmacology, Hamamatsu University School of Medicine, Shizuoka, Japan, **3** Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

* katsuei@yamanashi.ac.jp



OPEN ACCESS

Citation: Inoue O, Hokamura K, Shirai T, Osada M, Tsukiji N, Hatakeyama K, et al. (2015) Vascular Smooth Muscle Cells Stimulate Platelets and Facilitate Thrombus Formation through Platelet CLEC-2: Implications in Atherothrombosis. *PLoS ONE* 10(9): e0139357. doi:10.1371/journal.pone.0139357

Editor: Francis Miller, Jr., University of Iowa, UNITED STATES

Received: March 31, 2015

Accepted: September 11, 2015

Published: September 29, 2015

Copyright: © 2015 Inoue et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported in part by a Grant-in-Aid for scientific research from the Ministry of Education, Culture, Sports, Science, and Technology (YO, No.20390268, <https://www.jsps.go.jp/english/e-grants/index.html>), the Takeda Science Foundation (OI, <http://www.takeda-sci.or.jp/>), and the Japan Society for the Promotion of Science (JSPS) through the Funding Program for Next Generation World-leading Researchers (NEXT Program) initiated

Abstract

The platelet receptor CLEC-2 is involved in thrombosis/hemostasis, but its ligand, podoplanin, is expressed only in advanced atherosclerotic lesions. We investigated CLEC-2 ligands in vessel walls. Recombinant CLEC-2 bound to early atherosclerotic lesions and normal arterial walls, co-localizing with vascular smooth muscle cells (VSMCs). Flow cytometry and immunocytochemistry showed that recombinant CLEC-2, but not an anti-podoplanin antibody, bound to VSMCs, suggesting that CLEC-2 ligands other than podoplanin are present in VSMCs. VSMCs stimulated platelet granule release and supported thrombus formation under flow, dependent on CLEC-2. The time to occlusion in a FeCl₃-induced animal thrombosis model was significantly prolonged in the absence of CLEC-2. Because the internal elastic lamina was lacerated in our FeCl₃-induced model, we assume that the interaction between CLEC-2 and its ligands in VSMCs induces thrombus formation. Protein arrays and Biacore analysis were used to identify S100A13 as a CLEC-2 ligand in VSMCs. However, S100A13 is not responsible for the above-described VSMC-induced platelet activation, because S100A13 is not expressed on the surface of normal VSMCs. S100A13 was released upon oxidative stress and expressed in the luminal area of atherosclerotic lesions. Suspended S100A13 did not activate platelets, but immobilized S100A13 significantly increased thrombus formation on collagen-coated surfaces. Taken together, we proposed that VSMCs stimulate platelets through CLEC-2, possibly leading to thrombus formation after plaque erosion and stent implantation, where VSMCs are exposed to blood flow. Furthermore, we identified S100A13 as one of the ligands on VSMCs.

by the Council for Science and Technology Policy (CSTP) (KS-I, LS052, <http://www.jsps.go.jp/english/e-jisedai/incox.html>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Introduction

CLEC-2 has been identified as a receptor for the platelet-activating snake venom rhodocytin/aggrexin[1]. It elicits robust platelet aggregation through a tyrosine kinase-dependant signaling pathway[1]. We identified podoplanin as an endogenous ligand for CLEC-2 for the first time [2]. Podoplanin is expressed on the surface of tumor cells and induces platelet aggregation by binding to CLEC-2, facilitating hematogenous tumor metastasis[2, 3]. It is also expressed in lymphatic endothelial cells, but not in vascular endothelial cells[4]. CLEC-2-deficient mice show embryonic/neonatal lethality and blood-filled lymphatic vessels[5–7], suggesting that CLEC-2 facilitates blood/lymphatic vessel separation by interacting with podoplanin in lymphatic endothelial cells[8, 9].

Three studies reported that CLEC-2 plays a role in thrombosis and hemostasis[6, 10, 11], and one negative report has also been published[7]. May et al. showed that CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis, using mice with anti-CLEC-2 antibody-induced CLEC-2 deficiency[10]. Moreover, by transplantation of fetal liver cells from CLEC-2^{+/+} or CLEC-2^{-/-} embryos, we demonstrated that CLEC-2 is involved in thrombus stabilization *in vitro* and *in vivo*, possibly through homophilic interactions between pairs of CLEC-2 molecules, without an apparent increase in bleeding tendency[6]. In contrast, Hughes et al. showed that CLEC-2 is not required for platelet aggregation under arteriolar shear in an *in vitro* flow system[7]. However, it has recently been reported that combined *in vivo* depletion of the collagen receptor glycoprotein (GP) VI and CLEC-2 severely compromises hemostasis and abrogates arterial thrombosis in mice[11], indicating that CLEC-2 plays a role in thrombosis and hemostasis, although deletion of CLEC-2 alone produces a relatively minor phenotype. A tendency for severe bleeding in the absence of both receptors leads us to speculate that, along with CLEC-2, ligands for CLEC-2 are present in vessel walls (homophilic association). Therefore, identifying an endogenous ligand for CLEC-2 in vessel walls that contributes to thrombosis and hemostasis is important, since it may facilitate development of treatments for thrombosis and hemostasis.

In the present study, we demonstrated that VSMCs stimulate platelets through binding between CLEC-2 and its ligands. We identified S100A13 as one of the ligands, but found that it has limited potency; the other ligand remains unknown. Both may contribute to thrombus formation after plaque erosion and stent implantation, when VSMCs are exposed to blood flow. CLEC-2 ligands other than podoplanin are expressed on the surface of vascular smooth muscle cells (VSMCs) and that association between CLEC-2 and the ligand activates platelets and facilitates thrombus formation under flow conditions. We speculate that this association plays a pathophysiological role in thrombus formation after stent thrombosis and plaque erosion, when VSMCs are most likely to be exposed to blood flow. We identified S100A13 as the CLEC-2 ligand in VSMCs, although its physiological significance remains to be clarified.

Materials and Methods

Materials

An EnVision kit (rabbit IgG), Anti- α -smooth muscle actin (SMA; clone 1A4), and anti-CD68 (clone PGM-1) were purchased from Dako. The recombinant extracellular domain of human (h) or mouse (m) CLEC-2 was expressed as a dimeric human (h), rabbit (r), or rat immunoglobulin Fc domain fusion protein (hCLEC-2-hFc2, hCLEC-2-rFc2, or mouse CLEC-2-ratFc2); rFc2, hFc2, and ratFc2 were generated as described previously[2]. The GPVI agonist collagen-related peptide (CRP) was generated as previously described[12] by the Peptide Institute (Japan). Rhodocytin was generated as described previously[13]. GST-tagged S100A13

recombinant protein was purchased from CycLex Co., Ltd. (Japan) and His-tagged S100A13 recombinant protein was purchased from R&D Systems Inc. GST-tagged S100A13 recombinant protein was used for experiments unless otherwise noted. Other reagents were obtained from sources described below or previously described [6, 9].

In situ binding assay and immunohistochemistry

We used human abdominal aorta from a patient autopsied at the University of Miyazaki Hospital in 2001 after written informed consent was provided by the family. The Ethics Committees of the University of Miyazaki approved the study protocol (No.942) and the study was performed in accordance with the ethical standards of the Declaration of Helsinki. Several fresh aortic tissues (2 cm × 2 cm) were collected from atherosclerotic lesions of various degrees, and the specimens were frozen in Optimal Cutting Temperature (OCT) compound. Serial sections of the aortic intima (4 μm thick) were immunohistochemically stained with the indicated primary antibodies or recombinant proteins, as described previously using the EnVision kit [14, 15].

For the binding assay for the mouse aorta and lung tissue, perfusion fixation of 12-week-old C57BL/6 mice with 4% PFA/PBS was performed, and the abdominal aorta and lungs were harvested and fixed with 4% PFA/PBS for 2 h at 4°C. After washing in PBS, the tissues were equilibrated in 30% sucrose in PBS, embedded in OCT compound, and sectioned at 10-μm thickness. The sections were washed in PBS and blocked with 5% skim milk/PBS for 1 h. Each specimen was incubated with mCLEC-2-ratFc2 (25 μg/mL), rat Fc2 as a control (25 μg/mL), or anti-smooth muscle actin (Thermo Scientific) overnight at 4°C. Color detection was performed using Histofine Simple Stain MAX PO (rat and rabbit) and Histofine DAB-3S kit (Nichirei Biosciences, Japan) following the manufacturer's protocol. For podoplanin staining, each specimen was incubated with an anti-mouse podoplanin antibody (clone 8.1.1; Santa Cruz Biotechnology, Inc.) or control hamster IgG (Santa Cruz Biotechnology, Inc.). After rinsing with PBS, the samples were stained with anti-hamster IgG labeled with Alexa Fluor 488 (Life Technologies Inc.) for 2 h at 4°C. After rinsing with PBS, the cells were observed using an inverted fluorescence microscope IX71 (Olympus, Japan).

Where indicated, serial frozen-thawed sections of the mouse abdominal aorta from wild-type or ApoE-deficient mice fed a high fat diet were incubated with control rabbit IgG, anti-smooth muscle actin (Thermo Scientific, #RB-9010-P0), or anti-S100A13 antibody, followed by anti-rabbit IgG-Alexa Fluor 488. For co-staining for smooth muscle actin and S100A13, we used anti-α smooth muscle actin antibody (Abcam, ab21027), followed by anti-goat IgG Alexa Fluor 546 (Life Technologies Inc.). The sections were counter-stained with 4',6-diamidino-2-phenylindole (DAPI). The images are visualized a laser confocal microscope, FluoView (Olympus).

Cells

Human coronary artery smooth muscle cells (CASMCs) were purchased from Lonza and maintained on culture dishes in smooth muscle cell basic medium (SmBM) supplemented with SmGM-2 SingleQuots media (Lonza). 293TREx cells were obtained from Life Technologies Inc. Cultures were maintained at 37°C, 5% CO₂, and 100% humidity. To generate suspended CASMCs, we washed immobilized CASMCs in 10 cm culture dishes with PBS once, added 2 mL of trypsin/EDTA (0.025% trypsin, 0.02% EDTA), removed the trypsin/EDTA, incubated the dishes at 37°C for 2 min, and resuspended with PBS. After counting the number of cells, we centrifuged the suspended CASMCs at 180 g for 5 min, removed the supernatant, and resuspended the cells with PBS at the indicated cell concentrations.